Media Database
>
Scott Hensley

Scott Hensley

Digital Correspondent & Editor, Science Desk at NPR/National Public Radio Online

Contact this person
Email address
s*****@*******.orgGet email address
Phone
(XXX) XXX-XXXX Get mobile number
Location
United States
Covering topics
  • Health & Medicine
Languages
  • English
Influence score
75
Media Database
>
Scott Hensley
npr.org

FDA Panel Recommends Moderna’s COVID-19 Vaccine For Emergency Use

Advisers to the Food and Drug Administration voted 20-0 to recommend that the agency authorize Moderna’s vaccine for emergency use during the pandemic. There was a single abstention.
npr.org

The FDA Has Approved A New Alzheimer’s Drug — Here’s Why That’s Con...

This is the first new drug approved for Alzheimer’s disease since 2003. It’s the first to show significant progress against the sticky brain plaques that are the hallmark of Alzheimer’s disease.
npr.org

Pfizer’s COVID Vaccine Gets Full Approval From The FDA

The approval replaces the emergency use authorizations granted last December and could make it easier for employers, the military and universities to mandate vaccination.
npr.org

Pfizer Analysis Makes Case For COVID Vaccine Booster

Pfizer says data support its request for Food and Drug Administration approval of a third dose of COVID vaccine about six months after the second dose in people 16 years and older.
npr.org

FDA analysis of J&J COVID vaccine booster sets the stage for public...

Johnson & Johnson has asked the Food and Drug Administration to authorize a booster for people 18 and older six months after initial immunization, with an option to vaccinate after two months.
npr.org

An FDA panel of experts backs J&J COVID vaccine booster

A panel of experts voted to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID vaccine at least two months after the first shot.
npr.org

The FDA authorizes Moderna and J&J COVID vaccine boosters

The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.

Contact Scott Hensley and 1 million other journalists

Search by beat, location, outlet & position to find the right journalists for your story.

Sign up for free
npr.org

Moderna says COVID vaccine safe and effective for kids 6 to 11 ... ...

Moderna says a study in kids 6 to 11 found two doses of the company’s COVID-19 vaccine given 28 days apart produced a strong antibody response.
npr.org

CDC backs expansion of COVID boosters for all adults

CDC director Rochelle Walensky gave the green light to boosters just hours after a panel of vaccine advisors voted unanimously to recommend boosters for anyone 18 and older.
npr.org

An FDA panel supports Merck COVID drug in mixed vote

If the Food and Drug Administration authorizes use of the drug, called molnupiravir, it would be the first oral COVID-19 treatment that could be taken at home.
npr.org

Pfizer data shows that its COVID-19 pill is effective against sever...

The research finds that the medicine, called Paxlovid, was effective in preventing hospitalization and death when taken by people with mild to moderate illness within a few days of symptoms.
npr.org

FDA authorizes 1st antiviral pill for COVID

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer’s Paxlovid as the first antiviral pill to treat COVID-19 at home.
npr.org

FDA authorizes Merck COVID pill for home use

The medicine, called molnupiravir, is taken twice a day for five days and works by preventing the virus from replicating. Merck says it will have 10 million packs available by the end of the month.
npr.org

The FDA authorizes a Pfizer booster shot for children ages 12 to 15

The authorization comes in the midst of an explosion of COVID-19 cases nationwide driven by the omicron variant — a surge that has brought a spike in pediatric hospitalizations.
npr.org

Pfizer-BioNTech will seek authorization for second COVID booster fo...

Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.
npr.org

Advisers to FDA weigh in on updated COVID boosters for the fall

The vaccines now in use are based on the form of the virus that circulated at the beginning of the pandemic and are less effective against the omicron variant. New options are in the works.
npr.org

Advisers to the FDA back Novavax COVID vaccine

Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax’s two-dose vaccine against COVID-19.
npr.org

FDA authorizes first revamp of COVID vaccines to target omicron

The new shots from Moderna and Pfizer-BioNTech target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now.
npr.org

FDA committee votes to change and simplify U.S. COVID ... - NPR

Advisers to the U.S. Food and Drug Administration today endorsed a proposal to make big changes in the nation’s approach to vaccinating people against COVID-19.
npr.org

CDC experts recommend new COVID boosters : Shots - Health News - NPR

A panel of doctors and scientists advising the Centers for Disease Control and Prevention voted to recommend that people 6 months of age and older get new COVID boosters this fall.
npr.org

Nobel Prize recognizes scientists who laid groundwork for COVID ......

Hungarian-born biochemist Katalin Karikó and American immunologist Drew Weissman found that a chemical change to genetic code called mRNA eliminated a problematic side effect when used in vaccines.